Its ability to enhance BDNF, NGF, and GDNF signaling—while mitigating neurodegenerative deficits—positions S1R agonists as promising therapeutics for AD, PD, HD, and other disorders marked by neurotrophic factor depletion. This evidence concerns the gene TMBIM4 and Parkinson disease.